ADHD is a neurodevelopmental disorder. It is the most common neurodevelopmental disorder in children and adolescents. Its prevalence is estimated at 5.9% in this population. The symptoms of ADHD combine attention deficit with behavioural disorders such as hyperactivity and impulsivity. Current treatment for ADHD is based on psychotherapeutic and psychoeducational measures aimed at improving behaviour and its impact on the family, social and school environment. Drug treatments may also be used, depending on the impact of the disorder and the effectiveness of alternative treatments. Psychostimulants such as amphetamine derivatives and methylphenidate are around 80% effective.
Sulforaphane is an active substance derived from broccoli that has already been tested in the treatment of other neurodevelopmental disorders. The main hypothesis is that sulforaphane is effective in treating the symptoms of Attention Deficit Disorder with or without Hyperactivity (ADHD) in children.

Start Date01 Dec 2024

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

100 Clinical Results associated with Sulforadex

100 Translational Medicine associated with Sulforadex

100 Patents (Medical) associated with Sulforadex

3,500

Literatures (Medical) associated with Sulforadex

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Therapeutic potential of sulforaphane in neurodegenerative diseases: mechanistic Insights into Nrf2, NF-κB, TrkB, SIRT1, MAPK, and JAK/STAT signalling pathways

Review

Author: Pallavi ; Dhingra, Mamta Sachdeva ; Sharma, Akash ; Kuwar, Omkar Kumar ; Sharma, Vipul ; Rao, Aayush ; Attri, Mayank ; Tejpal, Sandip

Neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, and amyotrophic lateral sclerosis, are chronic and progressive disorders distinguished by neuronal dysfunction, oxidative stress, neuroinflammation, and abnormal protein aggregation. Due to the multifactorial nature of these disorders, current pharmacotherapies provide limited symptomatic relief without altering disease progression. Sulforaphane, a naturally occurring isothiocyanate abundant in cruciferous vegetables like broccoli, has emerged as a potent neuroprotective compound owing to its pleiotropic effects on key cellular signalling pathways. This review provides a thorough overview of the mechanistic insights underlying SFN’s neuroprotective potential, with a focus on the modulation of key signalling pathways such as Nrf2/ARE, NFĸB, BDNF/TrkB, SIRT1, MAPK, and JAK/STAT. Through the activation of antioxidant defenses and suppression of inflammatory cascades, SFN effectively mitigates neuronal damage and supports cellular homeostasis. Preclinical studies consistently demonstrate SFN’s ability to attenuate oxidative stress, inhibit apoptosis, preserve mitochondrial function, and improve neurobehavioral outcomes. While limited clinical evidence supports its safety and bioactivity, further investigations are needed to establish its therapeutic utility in human populations. Overall, SFN represents a promising natural compound with significant potential for the prevention and management of neurodegenerative diseases through multi-targeted pathway modulation.

01 Nov 2026·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Cooperative protein–ligand antioxidant activation: Sulforaphane binding to human serum immunoglobulin Genhances neuroprotection in spinal cord neurons via structural and functional modifications

Article

Author: Zhou, Yuxi ; Wang, Wei ; Wang, Danhua ; Yu, Shanshan ; Wu, Fenzan ; Zhang, Jinjing ; Lin, Tianjin ; Huang, Lichun ; Tan, Da ; Li, Shuo

Oxidative stress plays a central role in the progression of neurodegenerative damage, including spinal cord injury (SCI), where excessive reactive oxygen species (ROS) production leads to neuronal dysfunction and cell death. Although small-molecule antioxidants such as sulforaphane exhibit neuroprotective potential, their clinical efficacy is often limited by instability and poor bioavailability. In this study, we explore a cooperative protein-ligand strategy using human serum immunoglobulin G (HIgG) as a dynamic scaffold for sulforaphane binding and antioxidant modulation. An integrated experimental and computational approach combining multispectroscopy, molecular docking, molecular dynamics (MD) simulations, and in vitro neuronal assays was employed to characterize binding mechanism and antioxidant activity. Spectroscopic analyses confirmed spontaneous and moderately binding of sulforaphane to HIgG, primarily driven by hydrogen bonding and van der Waals interactions within the Fab region. MD simulations and CD data revealed that sulforaphane binding induces subtle but significant local conformational rearrangements in HIgG, enhancing solvent accessibility and flexibility of aromatic and redox-active residues. Functionally, in vitro experiments using spinal cord neurons under H₂O₂-induced oxidative stress demonstrated that the HIgG-sulforaphane complex provides significantly greater cytoprotection and ROS suppression than either component alone. In conclusion, these findings reveal a cooperative antioxidant mechanism in which HIgG-sulforaphane complex contribute to improved neuroprotective activity. This work highlights protein-ligand cooperativity as a promising strategy for designing next-generation antioxidant systems.

01 Oct 2026·BIORESOURCE TECHNOLOGY

Generative AI-driven enzyme engineering unlocks sustainable valorization of broccoli waste into sulforaphane

Article

Author: Guo, Siyuan ; Bao, Yihong ; Zhu, Ping ; Luo, Hao ; Lv, Fengxia ; Lu, Shan

Current production of sulforaphane (SFN), a health-promoting isothiocyanate, relies mainly on energy-intensive plant extraction or chemical synthesis, limiting sustainable large-scale manufacture. Here, a waste-to-value framework integrating generative artificial intelligence (AI), multi-scale modeling, and life-cycle assessment (LCA) was established to engineer a robust microbial biocatalyst for low-carbon valorization of broccoli waste. Genome mining identified a novel Lactobacillus-derived β-thioglucosidase as a promising scaffold. A ProteinMPNN-AlphaFold design pipeline targeting flexible loops near the active site yielded an improved variant with markedly enhanced catalytic performance and thermal robustness, with kcat increasing from 98.5 ± 3.2 to 421.3 ± 9.1 min^-1 and Km decreasing from 4.6 ± 0.2 to 0.9 ± 0.1 mM. Molecular dynamics and hybrid quantum mechanics/molecular mechanics (QM/MM) analyses indicated that loop rigidification, improved hydrophobic packing, and a reshaped electrostatic environment promoted transition-state stabilization and reduced the calculated activation barrier for SC bond cleavage from 19.2 to 17.5 kcal mol^-1. When applied to homogenized broccoli residues in a heterogeneous solid-liquid system, the engineered enzyme showed high SFN yields and broad tolerance across pH and temperature conditions. Comparative LCA further revealed ∼70% and ∼60% reductions in global warming potential and cumulative energy demand, respectively, relative to conventional routes. As the first study to integrate AI-driven protein engineering with rigorous sustainability metrics for SFN production, this work offers a scalable paradigm for the green biomanufacturing of high-value natural products from agricultural residues.

News (Medical) associated with Sulforadex

12 Jun 2026

·www.einpresswire.com

‘Outperform Cancer’ Spotlights Emerging Sulforaphane Research as Global Cancer Burden Reaches Record Levels

New clinical research highlights emerging evidence of sulforaphane synergies with cancer treatment drugs as the global cancer burden reaches record levels CHARLOTTE, VT, UNITED STATES, June 12, 2026 / EINPresswire.com / -- Outperform Cancer , founded by metastatic cancer survivor Marybeth Gilliam, is expanding its efforts to translate credible, emerging cancer research into accessible public conversation. The platform’s featured discussion with Dr. Jed W. Fahey — one of the world’s leading authorities on sulforaphane — explores the growing body of research on the phytochemical, now supported by 136 published human clinical studies. The conversation marks the latest effort by Outperform Cancer to connect patients, caregivers, and health professionals with scientifically credible perspectives on emerging areas of cancer research. The podcast arrives at a critical moment. Global cancer cases have more than doubled since 1990, reaching 18.5 million new diagnoses in 2023, with cases projected to rise a further 61% to 30.5 million by 2050 (GBD 2023 Cancer Collaborators, The Lancet, 2025). In the United States, more than 2.1 million new cancer cases are projected for 2026 alone (American Cancer Society, Cancer Facts & Figures, 2026). Over 40% of cancer deaths globally are linked to modifiable risk factors, including diet. Sulforaphane sits at a rare intersection of nutritional science and oncology. First isolated and identified as a potent cancer-preventive compound by the late Dr. Paul Talalay at Johns Hopkins University School of Medicine in 1992, sulforaphane has since been the subject of more than 3,000 published studies. A landmark new peer-reviewed paper published in the journal Medicines (May 2026) by Dr. Fahey and colleagues reviews published evidence describing potential synergistic interactions between sulforaphane and cancer treatment drugs across eleven cancer types, including bladder, blood, brain, breast, colon, esophageal, liver, lung, ovarian, prostate, and skin cancers. The review highlights preclinical and emerging translational evidence suggesting that sulforaphane may influence treatment response, tolerability, and therapeutic effectiveness when paired with certain conventional therapies. In the featured Outperform Cancer episode, “Can Broccoli Sprouts Fight Cancer? What 30 Years of Research Shows,” Dr. Fahey discusses sulforaphane’s mechanisms of action, its roles in activating the body’s cellular defense and detoxification pathways, effects on cancer stem cells, and the growing body of evidence supporting its study alongside conventional cancer treatments. As a long-term metastatic cancer survivor, Gilliam recognized that emerging research in nutrition, metabolism, and food-derived bioactives often remains confined to academic journals for many years before it reaches patients or clinical practice. Living with metastatic cancer much longer than indicated by her original prognosis, Gilliam has dedicated herself to helping patients access credible scientific information and thoughtfully explore emerging areas of research that may one day influence standards of care. She founded Outperform Cancer to help bridge that gap through credible, contextualized public conversations with scientists, physicians, and researchers. Listen to the Episode Dr. Jed Fahey: Can Broccoli Sprouts Fight Cancer? What 30 Years of Research Shows www.outperformcancer.com Related Publication Fahey, J.W. and H. Liu. Sulforaphane Synergies with Phytochemicals and Pharmaceuticals: Implications for Healthspan. Medicines 2026, 13(2), 16. https://doi.org/10.3390/medicines13020016 About Outperform Cancer Outperform Cancer is a science-driven media and education platform founded by Marybeth Gilliam, dedicated to translating emerging cancer research into accessible public conversations on prevention, survivorship, nutrition, and healthspan. www.outperformcancer.com About Dr. Jed W. Fahey Dr. Jed W. Fahey, M.S., Sc.D., is widely recognized as one of the world's foremost authorities on sulforaphane. Working alongside the late Dr. Paul Talalay, he helped pioneer the scientific exploration of sulforaphane and later co-founded and directed the Cullman Chemoprotection Center at The Johns Hopkins University School of Medicine. He now focuses his work on sulforaphane, other phytochemicals, and their potential to support healthspan. See www.jedfahey.com for Dr. Fahey’s publications and podcasts. Marybeth Gilliam Outperform Cancer email us here Visit us on social media: Instagram YouTube Other Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

21 May 2026

·www.einpresswire.com

Comprehensive Review Catalogues 136 Human Clinical Studies on Sulforaphane and Broccoli Bioactives

Compendium Highlights Broad Use of TrueBroc® in Clinical Studies This body of work reflects the remarkable evolution of sulforaphane research over the past 30 years.” — Dr. Jed Fahey BALTIMORE, MD, UNITED STATES, May 21, 2026 / EINPresswire.com / -- A newly published peer-reviewed paper in Medicines examines the expanding body of research on sulforaphane — the bioactive compound derived from broccoli , broccoli seeds and sprouts, and cruciferous vegetables — highlighting its synergistic interactions with phytochemicals and pharmaceuticals across a wide range of health applications. The publication, “Sulforaphane Synergies with Phytochemicals and Pharmaceuticals: Implications for Healthspan,” was authored by Dr. Jed W. Fahey and Dr. Hua Liu of Johns Hopkins School of Medicine and published on May 6, 2026. Accompanying the paper is a detailed supplemental compendium cataloging 136 human clinical studies using glucoraphanin, sulforaphane, broccoli sprouts, broccoli seed extract(s), or related interventions — spanning metabolic health, cognitive health, inflammation modulation, cardiovascular function, aging, detoxification, autism spectrum disorder, schizophrenia, oncology, and bioavailability research. The supplemental table documents three decades of clinical investigation dating back to 1998 and is updated as of March 15, 2026, to include the most recent activity. “This body of work reflects the remarkable evolution of sulforaphane research over the past 30 years,” said Jed W. Fahey, ScD. “What began as foundational cancer chemoprotection research has expanded into a much broader exploration of oxidative stress, inflammation, epigenetics, detoxification, and cellular resilience.” The review highlights multiple strands of evidence suggesting that sulforaphane may act synergistically with phytochemicals, including EGCG, curcumin, selenium, and quercetin, as well as chemotherapy agents, targeted therapies, and immunotherapies. Across multiple models, researchers observed positive effects on Nrf2-mediated cytoprotective and glutathione-related pathways, apoptosis, modulation of inflammation, oxidative stress response, epigenetic regulation, and cancer stem cell signaling. The publication also underscores the importance of understanding the specifics of interventions to ensure they deliver appropriate quality and dosage, as well as the bioavailability of sulforaphane, given sulforaphane’s significant instability. Many of these studies utilized the TrueBroc ® family of ingredients, which are commercially available sulforaphane-related ingredients used in nutritional supplements. Notably, internal analysis of the subset of clinical studies utilizing commercially available preparations (rather than laboratory-developed or pre-commercial materials) indicates that approximately 79% of the broccoli seed and sprout interventions utilized the TrueBroc ® family of ingredients. The review is dedicated to the memory of Professor Thomas W. Kensler (1948–2025), whose pioneering contributions helped shape the modern understanding of the beneficial properties of sulforaphane and broccoli. TrueBroc ® encompasses a family of broccoli seed-focused ingredients developed to support clinically informed formulation and enhanced sulforaphane bioavailability, building upon decades of foundational research advanced by pioneering scientists, including Dr. Jed Fahey and the late Dr. Paul Talalay. The emerging synergy data further underscores sulforaphane’s potential as a multi-pathway compound with growing relevance to next-generation therapeutic and nutritional strategies. Publication: Fahey JW, Liu H. (2026). Sulforaphane Synergies with Phytochemicals and Pharmaceuticals: Implications for Healthspan. Medicines. 13(2):16. https://www.mdpi.com/2305-6320/13/2/16 M. Raphaely Brassica Protection Products +1 410-732-1200 email us here Visit us on social media: LinkedIn Instagram Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

23 Mar 2026

·www.einpresswire.com

Human Microbiome Genes Correlate with Sulforaphane Bioavailability in Controlled Clinical Study

These findings strengthen the evidence that microbiome composition plays a substantive role in sulforaphane formation in the gut” — Sue Ishaq, PhD BALTIMORE, CA, UNITED STATES, March 23, 2026 / EINPresswire.com / -- A newly published human clinical study reports correlations between specific gut microbial genes and an individual’s ability to convert glucoraphanin — the dietary precursor to sulforaphane — into its bioactive form. “For decades, we have understood the biological potency of sulforaphane,” said Jed W. Fahey, ScD, a co-author of the study and a leading authority in glucosinolate research. “What has remained less clear is how consistently individuals can generate it from dietary precursors. This work advances our understanding of the factors contributing to variability in sulforaphane formation.” The study, published in Scientific Reports, a peer-reviewed journal within the Nature Portfolio, represents the first controlled human clinical investigation to correlate previously characterized glucoraphanin-converting bacterial genes with measured in vivo sulforaphane formation. Sulforaphane, a widely studied plant bioactive known for activating Nrf2-regulated antioxidant and detoxification pathways, is formed from glucoraphanin via enzymatic conversion. While plant-derived myrosinase can catalyze this reaction, the human gut microbiome can also contribute, with conversion capacity varying substantially between individuals. Researchers observed significant correlations between sulforaphane production and the relative abundance of previously characterized glucoraphanin-metabolizing genes. Participants with higher gene abundance demonstrated greater conversion efficiency. Higher conversion was also observed among participants with greater Bifidobacterium abundance, further supporting a role for microbiome composition in the formation of sulforaphane. The findings also suggest that prior exposure to glucoraphanin may influence subsequent microbial capacity for conversion, consistent with microbiome adaptation. By linking microbial gene presence with measured sulforaphane formation, the study provides new insight into variability in individual conversion capacity and contributes to growing research examining how the gut microbiome influences dietary phytochemical metabolism. “These findings strengthen the evidence that microbiome composition plays a substantive role in sulforaphane formation in the gut,” said Sue Ishaq, PhD, microbiome researcher and a co-author of the study. “Differences in microbiome composition may help explain why individuals vary in how effectively they convert glucoraphanin.” The research was conducted as a collaboration with investigators from North Carolina State University, the University of Maine, Appalachian State University, and Brassica Protection Products. The study appears in Scientific Reports: https://www.nature.com/articles/s41598-026-39389-4 Mirran Raphaely Brassica Protection Products +1 707-854-5840 email us here Visit us on social media: LinkedIn Instagram Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Microbial therapyClinical Study

100 Deals associated with Sulforadex

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12422

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Respiratory Distress Syndrome, Adult	Phase 3	United Kingdom	TheraCryf Plc	23 Nov 2020
SARS-CoV-2 acute respiratory disease	Phase 3	United Kingdom	TheraCryf Plc	19 Sep 2020
Acute respiratory infections	Phase 2	United Kingdom	TheraCryf Plc	04 Sep 2020
Community Acquired Pneumonia	Phase 2	United Kingdom	TheraCryf Plc	04 Sep 2020
Infectious Lung Disorder	Phase 2	United Kingdom	TheraCryf Plc	04 Sep 2020
Respiratory Distress Syndrome, Acute	Phase 2	United Kingdom	TheraCryf Plc	04 Sep 2020
ER-positive/HER2-negative Breast Cancer	Phase 2	Belgium	-	01 Oct 2016
ER-positive/HER2-negative Breast Cancer	Phase 2	France	-	01 Oct 2016
ER-positive/HER2-negative Breast Cancer	Phase 2	Spain	-	01 Oct 2016
ER-positive/HER2-negative Breast Cancer	Phase 2	United Kingdom	-	01 Oct 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05797506 (CTgov)	Phase 2	Chronic Kidney Diseases	96	Sulforaphane (Sulforaphane (Avmacol Extra Strength))	jmewwhmwkd(pyezwhlegk) = zldbqzxmko zwknkyhlwf (zektmniwek, 121.65) View more	-	18 May 2026
				Placebo (Placebo)	jmewwhmwkd(pyezwhlegk) = mkrzhbytag zwknkyhlwf (zektmniwek, 129.43) View more
NCT03232138 (CTgov)	Phase 2	Lung Cancer	43	Sulforaphane (Sulforaphane (Study Drug))	rlumzvowva(neewxwiynz) = kdqfzlawlw rmqhgamrat (aetnuksmvb, 0.38) View more	-	17 Dec 2024
				Placebo (Placebo)	rlumzvowva(neewxwiynz) = qttjjhrxwi rmqhgamrat (aetnuksmvb, 0.41) View more
NCT05153174 (CTgov)	Phase 1	Chronic Kidney Diseases	18	Sulforaphane (2 Tablets of Sulforaphane)	ojxjebwbfa(vvlnuappeh) = cgkamakwyh xygzqhuypr (sdyfcajefb, 376.5) View more	-	12 Aug 2024
				Sulforaphane (4 Tablets of Sulforaphane)	ojxjebwbfa(vvlnuappeh) = muggpsbkzn xygzqhuypr (sdyfcajefb, 335.8) View more
NCT02614742 (SAS Study, Pubmed)	Phase 2	Subarachnoid Hemorrhage	105	SFX-01 300 mg BD	uuprnwbwou(ujywpcphhe) = 9 SFX-01 (16.7%), 1 placebo (2.0%) lykpnlmlxi (ygztedjgio )	Negative	19 Jul 2024
EUCTR2020-003486-19-GB (Pubmed)	Phase 2	Community Acquired Pneumonia	133	SFX-01	hbiltmvkcs(ligeczppko): 0.87 (95% CI, 0.41 - 1.83), P-Value = 0.71 View more	Negative	11 Mar 2024
				安慰剂
ERS2022	Not Applicable	COVID-19	133	S-SFN 300mg	tejuefpufm(fbtrqqdamz) = lkoontydsh jvorvkxgxc (dwvegsozwq )	Negative	04 Sep 2022
				Placebo	tejuefpufm(fbtrqqdamz) = ysiuwvlein jvorvkxgxc (dwvegsozwq )
NCT02810964 (CTgov)	Phase 2	Schizoaffective disorder \| Schizophrenia	64	Sulforaphane (Sulforaphane Nutraceutical)	pezvibfxdw(shwzrpfajg) = etokwrgzfs vwcquwkrtl (zyhmaspbef, 12.2) View more	-	27 Jul 2021
				Identical-appearing Placebo (Identical-appearing Placebo)	pezvibfxdw(shwzrpfajg) = ydmcozwikn vwcquwkrtl (zyhmaspbef, 13.0) View more
NCT02561481 (Pubmed \| Mol Autism) Manual	Phase 1/2	Autism Spectrum Disorder	57	sulforaphane	gnxiwdrogn(hrqyvlbpde) = fgfdqpqpjs rxzyghkruu (ucwacskzmx, -0.46 to 0.88) View more	Negative	25 May 2021
				Placebo	gnxiwdrogn(hrqyvlbpde) = ftppffxzgr rxzyghkruu (ucwacskzmx, -0.52 to 0.72)
NCT02561481 (CTgov)	Phase 1/2	Autism Spectrum Disorder	60	Sulforaphane (Sulforaphane)	bdnptvajar(fmidwhwazm) = fuiltfgcoq budxxpmwgy (auqiiumbqg, 0.67) View more	-	25 Nov 2020
				Placebo (Placebo)	bdnptvajar(fmidwhwazm) = mehwqtwltk budxxpmwgy (auqiiumbqg, 0.57) View more
NCT02909959 (CTgov)	Phase 2	Autism Spectrum Disorder \| Autistic Disorder \| Pervasive child development disorders	48	Sulforaphane (Sulforaphane)	wmkozmqnis(vkssmgupsq) = wquicmtbrh abgjhqslal (oywyjndake, 7.4) View more	-	15 May 2020
				Placebo (Placebo)	wmkozmqnis(vkssmgupsq) = myeajgbptz abgjhqslal (oywyjndake, 4.6) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis